A5073137060- Lung Cancer Treatments and Mutations
- Glioma Diagnosis and Treatment
- Lung Cancer Diagnosis and Treatment
- Lung Cancer Research Studies
- Brain Metastases and Treatment
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Cancer Genomics and Diagnostics
- Gastric Cancer Management and Outcomes
- Head and Neck Cancer Studies
- Meningioma and schwannoma management
- Neuroendocrine Tumor Research Advances
- Esophageal Cancer Research and Treatment
- Cancer, Hypoxia, and Metabolism
- Economic and Financial Impacts of Cancer
- Gastrointestinal Tumor Research and Treatment
- Metabolism, Diabetes, and Cancer
- Radiomics and Machine Learning in Medical Imaging
- Hepatocellular Carcinoma Treatment and Prognosis
- Digital and Traditional Archives Management
- PI3K/AKT/mTOR signaling in cancer
- Cancer survivorship and care
- Cancer-related cognitive impairment studies
- HER2/EGFR in Cancer Research
- Autism Spectrum Disorder Research
McGill University Health Centre
2014-2025
Montreal General Hospital
2024-2025
McGill University
2013-2024
Montreal Neurological Institute and Hospital
2014-2024
Jewish General Hospital
2024
Nunavik Regional Board of Health and Social Services
2024
Riley Hospital for Children
2024
University of California, San Francisco
2018
Marshfield Clinic
2015
University of Winnipeg
2015
Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) phase I studies. These combinations were evaluated a global III trial.
Amivantamab-lazertinib significantly prolonged progression-free survival (PFS) versus osimertinib in patients with epidermal growth factor receptor (EGFR)-mutant advanced non-small-cell lung cancer [NSCLC; hazard ratio (HR) 0.70; P < 0.001], including those a history of brain metastases (HR 0.69). Patients TP53 co-mutations, detectable circulating tumor DNA (ctDNA), baseline liver metastases, and without ctDNA clearance on treatment have poor prognoses. We evaluated outcomes these high-risk...
The open-label, phase III EVOKE-01 study evaluated sacituzumab govitecan (SG) versus standard-of-care docetaxel in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based chemotherapy, anti-PD-(L)1, and targeted treatment for actionable genomic alterations (AGAs). Primary analysis is reported.
Background: Nivolumab was the first immuno-oncology agent available for treatment of lung cancer in Canada. In present study, we evaluated real-world benefit nivolumab Canadian patients with cancer. Methods: Patients included cohort were identified from a registry treated through expanded access to before and after Health Canada approval. Demographics collected application forms. Outcome data duration survival retrospectively. Results: contrast randomized clinical trial populations, our...
Anti-PD-1 has activity in brain metastases (BM). This phase II open labeled non-randomized single arm trial examined the safety and efficacy of combining nivolumab with radiosurgery (SRS) treatment patients BM from non-small cell lung cancer (NSCLC) renal carcinoma (RCC).This was a multicenter (NCT02978404) which diagnosed NSCLC or RCC, having ≤ 10 cc un-irradiated no prior immunotherapy were eligible. Nivolumab (240 mg 480 IV) administered for up to 2 years until progression. SRS (15-21 Gy)...
LBA8500 Background: In pts with mNSCLC who progress on PT-based chemo and IO, doc is standard of care, but outcomes remain poor. SG, a Trop-2-directed antibody drug conjugate, showed durable response tolerable safety in pretreated mNSCLC. We report results from the phase 3, randomized, open-label EVOKE-01 study comparing SG vs doc. Methods: Pts disease progression after IO were randomized 1:1 (stratified by histology, best to last prior treatment for actionable genomic alterations [yes/no])...
Aim: To assess the cost-effectiveness in Canada of atezolizumab compared with docetaxel or nivolumab for treatment advanced NSCLC after first-line platinum-doublet chemotherapy.Materials and methods: A three-state partitioned-survival model was developed. Clinical inputs were obtained from phase III OAK trial comparing patients who progressed chemotherapy. Overall survival (OS) progression-free (PFS) extrapolated beyond period using parametric models. cure assuming a 1% fraction fitted to OS...
TPS9146 Background: Most patients (pts) with advanced NSCLC do not harbor genomic alterations associated approved first-line targeted therapies. The standard of care for these pts is a programmed death (ligand)-1 (PD-[L]1) inhibitor alone, if the tumor highly expresses PD-L1, or in combination platinum doublet chemotherapy, independent PD-L1 expression. However, most respond to therapies achieve only transient response, highlighting an unmet need. SG antibody-drug conjugate composed...
// Jad Alshami 1 , Marie-Christine Guiot Scott Owen Petr Kavan Neil Gibson 2 Flavio Solca 3 Agnieszka Cseh David A. Reardon 4 Thierry Muanza 1, 5 Clinical Research Unit, Montreal Neurological Institute and Hospital, McGill University Health Center, Montreal, Canada Drug Metabolism & Pharmacokinetics, Boehringer Ingelheim Pharma GmbH Co. KG, Biberach, Germany RCV Vienna, Austria Center for Neuro-Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts, USA Radiation Oncology, Jewish...
The optimal fractionation schedule of radiotherapy (RT) for Glioblastoma multiforme (GBM) is yet to be determined. We aim compare different regimens and identify prognostic factors better tailor RT newly diagnosed GBM patients.All data patients who underwent surgery between January 2005 December 2012 were compiled. Clinical information was collected using patient charts government registry. Cox analysis used variables affecting survival treatment outcome.The median follow-up time 13.2...
Amivantamab (ami) is an EGFR-MET bispecific antibody with immune cell-directing activity. In MARIPOSA-2 (NCT04988295), ami plus carboplatin-pemetrexed (ami-chemo) significantly prolonged progression-free survival (PFS) vs chemo in patients (pts) EGFR-mutant advanced NSCLC after progression on osimertinib (Passaro Ann Oncol 2023). Post-progression outcomes from were assessed. 657 pts randomized. These analyses focus the 131 randomized to ami-chemo (safety: n=130) and 263 n=243). A third arm...